Cutoff Values of MASK-air Patient-Reported Outcome Measures.
Sousa-Pinto B., Sá-Sousa A., Vieira RJ., Amaral R., Pereira AM., Anto JM., Klimek L., Czarlewski W., Mullol J., Pfaar O., Bedbrook A., Brussino L., Kvedariene V., Larenas-Linnemann DE., Okamoto Y., Ventura MT., Ansotegui IJ., Bosnic-Anticevich S., Canonica GW., Cardona V., Cecchi L., Chivato T., Cingi C., Costa EM., Cruz AA., Del Giacco S., Devillier P., Fokkens WJ., Gemicioglu B., Haahtela T., Ivancevich JC., Kuna P., Kaidashev I., Kraxner H., Laune D., Louis R., Makris M., Monti R., Morais-Almeida M., Mösges R., Niedoszytko M., Papadopoulos NG., Patella V., Pham-Thi N., Regateiro FS., Reitsma S., Rouadi PW., Samolinski B., Sheikh A., Sova M., Taborda-Barata L., Toppila-Salmi S., Sastre J., Tsiligianni I., Valiulis A., Yorgancioglu A., Zidarn M., Zuberbier T., Fonseca JA., Bousquet J.
BackgroundIn clinical and epidemiological studies, cutoffs of patient-reported outcome measures can be used to classify patients into groups of statistical and clinical relevance. However, visual analog scale (VAS) cutoffs in MASK-air have not been tested.ObjectiveTo calculate cutoffs for VAS global, nasal, ocular, and asthma symptoms.MethodsIn a cross-sectional study design of all MASK-air participants, we compared (1) approaches based on the percentiles (tertiles or quartiles) of VAS distributions and (2) data-driven approaches based on clusters of data from 2 comparators (VAS work and VAS sleep). We then performed sensitivity analyses for individual countries and for VAS levels corresponding to full allergy control. Finally, we tested the different approaches using MASK-air real-world cross-sectional and longitudinal data to assess the most relevant cutoffs.ResultsWe assessed 395,223 days from 23,201 MASK-air users with self-reported allergic rhinitis. The percentile-oriented approach resulted in lower cutoff values than the data-driven approach. We obtained consistent results in the data-driven approach. Following the latter, the proposed cutoff differentiating "controlled" and "partly-controlled" patients was similar to the cutoff value that had been arbitrarily used (20/100). However, a lower cutoff was obtained to differentiate between "partly-controlled" and "uncontrolled" patients (35 vs the arbitrarily-used value of 50/100).ConclusionsUsing a data-driven approach, we were able to define cutoff values for MASK-air VASs on allergy and asthma symptoms. This may allow for a better classification of patients with rhinitis and asthma according to different levels of control, supporting improved disease management.